Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART2019.1 in Relapsed or Resistant B-NHL
NCT03870945Phase 1Completed
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Feb 2019
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of zamtocabtagene autoleucel in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Miltenyi Biomedicine GmbH. Primary endpoints: Maximum Tolerated Dose at 28 days and Safety and Toxicity Assessment at 28 days. Started Feb 2019; status: completed.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03870945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870945.